NCT06690801 Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome
| NCT ID | NCT06690801 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Children's Hospital Los Angeles |
| Condition | Acute Respiratory Distress Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,260 participants |
| Start Date | 2024-10-03 |
| Primary Completion | 2028-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,260 participants in total. It began in 2024-10-03 with a primary completion date of 2028-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to determine whether a marker of dead space (the end-tidal to alveolar dead space fraction \[AVDSf\]) is more strongly associated with mortality risk than markers of oxygenation abnormality (oxygenation index) and to determine whether dead space (AVDSf) is an important marker of heterogeneity in the inhaled nitric oxide (iNO) treatment effect for children with acute respiratory distress syndrome (ARDS). The study aims are: 1. To validate AVDSf for risk stratification of mortality in pediatric ARDS 2. To determine if there is heterogeneity in treatment effect for iNO defined by AVDSf 3. To detect the association between AVDSf and microvascular dysfunction trajectory and whether iNO therapy modifies this association This is a prospective, multicenter observational study of 1260 mechanically ventilated children with moderate to severe ARDS. In a subgroup of 450 children with severe ARDS, longitudinal blood samples will be obtained to measure plasma protein markers.
Eligibility Criteria
Inclusion Criteria: * Age \>37 weeks corrected gestational age to 21 years, including adults lacking the capacity to consent. * Within 72 hours of the start of invasive mechanical ventilation and meet the criteria for pediatric ARDS (new infiltrate on chest imaging and a known ARDS risk factor within 7 days of the onset of hypoxemia) and either meet criteria for moderate or severe pediatric ARDS between 4-72 hours of IMV (OI ≥ 8 or OSI ≥ 7.5) OR have an OI ≥ 20 or an OSI ≥ 14 x 15 minutes between 0-4 hours of IMV. * Subgroup of children eligible for longituduinal Blood Collection: Children with severe PARDS (OI ≥ 16 or an OSI ≥ 12 between 4-72 hours of IMV) or those with an OI ≥ 20 or an OSI ≥ 14 for 15 minutes between 0-4 hours of IMV will be eligible for collection of longitudinal plasma samples. Exclusion Criteria: * Non-conventional invasive mechanical ventilation (i.e. High Frequency Oscillatory Ventilation, Airway Pressure Release Ventilation) at the time of ICU admission * ECMO or iNO (or other inhaled pulmonary vasodilator therapy) at the time of ICU admission * Significant lower airways obstruction (examination of ventilator and capnography waveforms by site study or medical team) * Air leak \>20% (endotracheal tube, tracheostomy tube, or thoracostomy tube) * Home Invasive Mechanical Ventilation * Cyanotic Congenital Heart Disease * Previous enrollment in the DiNO study * Do not resuscitate order at the time of pediatric ARDS diagnosis. * Blood gas not obtained prior to initiation of ECMO, iNO, or non-conventional ventilation.
Contact & Investigator
Anoopindar M Bhalla, MD
PRINCIPAL INVESTIGATOR
Children's Hospital Los Angeles
Frequently Asked Questions
Who can join the NCT06690801 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 21 Years, studying Acute Respiratory Distress Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06690801 currently recruiting?
Yes, NCT06690801 is actively recruiting participants. Contact the research team at dinostudy@chla.usc.edu for enrollment information.
Where is the NCT06690801 trial being conducted?
This trial is being conducted at Los Angeles, United States, Denver, United States, Boston, United States, Ann Arbor, United States and 6 additional locations.
Who is sponsoring the NCT06690801 clinical trial?
NCT06690801 is sponsored by Children's Hospital Los Angeles. The principal investigator is Anoopindar M Bhalla, MD at Children's Hospital Los Angeles. The trial plans to enroll 1,260 participants.